Worried About a Market Crash? This Dividend Stock Outperformed as the S&P 500 Sank in Both 2008 and 2022

Amgen is presented as a defensive equity for a potential market downturn, supported by historical relative resilience during the 2008 financial crisis and the 2022 bear market. Despite denosumab products Prolia and Xgeva accounting for nearly 20% of 2024 revenue before loss of exclusivity, Q2 revenue rose 10% year over year to $10.1 billion, with 22 products delivering double-digit sales growth. The company also offers a 2.6% dividend yield versus the S&P 500 average of 1.1%, while pipeline assets MariTide and olpasiran provide longer-term growth potential despite clinical-development risk.

Analysis

The relevant question is not whether AMGN is defensive, but whether investors are being paid for that defensiveness. Its earnings stream has lower macro beta than cyclicals, yet the market will focus on whether post-acquisition leverage can decline while biosimilar erosion in the bone franchise accelerates. If revenue replacement remains execution-dependent, AMGN can behave less like a bond proxy and more like a pipeline-risk large-cap pharma; dividend support alone is unlikely to prevent multiple compression if free-cash-flow conversion disappoints.

The NVS outcome raises the required proof threshold for the entire Lp(a) category: biomarker reduction does not necessarily translate into cardiovascular-event benefit. That primarily affects AMGN's medium-term terminal-value assumptions rather than near-term earnings, but it makes upcoming olpasiran trial design, baseline-risk mix, and event-rate disclosures more important than headline Lp(a) lowering. Conversely, AMGN's obesity asset creates a potentially underappreciated asymmetric catalyst over 6-18 months if durability, tolerability, and lean-mass outcomes differentiate it from GLP-1 incumbents; absent that differentiation, the market is unlikely to award a meaningful obesity multiple.

Near term, this is more suitable as a defensive relative-value exposure than a standalone momentum long. A broad risk-off move could favor AMGN versus high-duration growth within days to weeks, but the 1-3 month stock-specific catalyst path depends on guidance durability, biosimilar commentary, and deleveraging. Falsify a constructive view if management cuts annual revenue/FCF guidance, net-debt reduction stalls, or biosimilar share loss exceeds assumptions; falsify the bearish pipeline view if olpasiran produces credible outcomes evidence or MariTide data demonstrate differentiated efficacy with acceptable discontinuation rates.

Key Decisions for Investors

• Use AMGN as a 1-3 month defensive pair: long AMGN / short XLK or a basket of higher-beta large-cap growth, sized market-neutral. The payoff is relative downside protection in a volatility shock; exit if AMGN underperforms the hedge by 5% after a broad-market drawdown, signaling stock-specific concerns outweigh defensiveness.
• Do not add outright AMGN solely on the dividend narrative before the next earnings update. Establish an alert for reaffirmed FCF guidance plus measurable net-debt reduction; confirmation would support a 6-12 month long, while a guidance reset or weaker capital-return capacity argues for avoiding the name.
• Treat olpasiran as a watch-item rather than a catalyst long. Before initiating exposure ahead of pivotal readouts, require clarity on event-driven endpoint timing and statistical powering; the NVS result increases binary downside and makes pre-data ownership unattractive without a favorable implied pipeline value.
• For healthcare defensiveness, prefer a diversified sleeve via XLV over concentrated AMGN until biosimilar erosion and pipeline valuation are better bounded. AMGN can be added selectively if its valuation discount to large-cap pharma compensates for the added clinical and balance-sheet risk.